GlassScriptPhysician profile
Robert T Gillespie
NPI 1922026467
$1,994.38
in general payments reported to CMS, 2019-2025
21 companies · $864 in 2025
The $864 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $350 · 2022: $333 · 2023: $82.29 · 2024: $364 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,311.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $460.20 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Organogenesis INC. | $427.99 | 2021-2025 | Apligraf, Novachor, Nushield |
| Abbvie INC. | $355.88 | 2021-2025 | |
| Mimedx Group, INC. | $126.43 | 2024-2025 | |
| Lilly USA, LLC | $113.16 | 2021-2022 | |
| Reprise Biomedical, INC. | $95.13 | 2025 | Miro3d |
| Smith+Nephew, INC. | $76.18 | 2023-2025 | Grafix Pl, Renasys Go V2 Home, Oasis |
| Solventum Corporation | $71.23 | 2024-2025 | Activ.A.C., Kerramax Care, 3m Cavilon |
| Sunovion Pharmaceuticals INC. | $44.93 | 2021 | |
| Boston Scientific Corporation | $36.46 | 2021-2022 | |
| Kci USA, INC. | $28.65 | 2023 | Activ.A.C., V.A.C. Dermatac, Promogran |
| Novo Nordisk INC | $27.55 | 2021-2022 | |
| Amgen INC. | $18.43 | 2021 | |
| Corcept Therapeutics | $16.62 | 2024 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $15.32 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $14.64 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.72 | 2021 | |
| Jazz Pharmaceuticals INC. | $13.68 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.20 | 2021 | |
| Supernus Pharmaceuticals, INC. | $12.93 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gillespie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.